Clinical Trial Update: A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating cobimetinib alone or with venetoclax, with or without atezolizumab, in relapsed/refractory multiple myeloma; study completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Cobimetinib (cobimetinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-02-28